H.C. Wainwright downgraded Optinose (OPTN) to Neutral from Buy with a $9 price target after Paratek Pharmaceuticals announced it will be acquiring the company for $9 per share up front and contingent value rights worth up to $5 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPTN:
- Optinose downgraded to Neutral from Overweight at Piper Sandler
- Hold Rating Issued Amid Optinose Acquisition by Paratek Pharmaceuticals with Adjusted Price Target
- Optinose downgraded to Hold from Buy at Lake Street
- Paratek Pharmaceuticals to acquire Optinose in $330M transaction
- OptiNose trading resumes